FTI Consulting Survey Finds Healthcare Leaders View Trustworthiness as Most Important Quality for Next Food and Drug Administration Commissioner
Four in Five Believe Diversity in Clinical Trials Will Be as Important as Safety and Efficacy
While a majority of respondents (59%) identified COVID-19 disruptions as the greatest risk to industry for the second year in a row, 36% expect talent scarcity to be a high risk to companies in 2022, up from 22% last year, with just over two in 10 claiming they are “fully prepared” to meet this challenge.
“We are delighted to share the findings of our second annual industry outlook, which demonstrate the need for healthcare leaders to make a renewed commitment to diversity, ethics and inclusive engagement,” said
As the industry emerges from the pandemic, diversity, equity, inclusion and talent retention are top-of-mind for the industry:
- 82% of respondents are confident that diversity in clinical trials will become equally important alongside safety and efficacy in the next 12 months.
- When considering diversity, equity and inclusion, recruitment (52%) and retention of diverse talent (45%) are two top areas of focus for companies in 2022.
The regulatory environment and political risk to industry remain a top concern for healthcare executives:
- Companies expect political risk to increase over the next 12 months, with more than one in three (36%) concerned about the political environment, up 6% from last year.
- More than two-thirds (69%) of industry executives expect significant policy changes will be made on drug pricing under the Biden administration in the next 12 months.
There is also increasing confidence that deal activity will rebound over the next 12 months:
- Nearly two-thirds (65%) of respondents expect IPO and M&A activity to be higher in 2022.
- There is substantial confidence in IPO activity rebounding, with approximately one-quarter (24%) of industry leaders believing IPO activity will be “far higher” next year.
- The majority (57%) of industry leaders foresee higher SPAC activity in 2022 than in the previous 12 months.
“Similar to an increasing call over recent years for a social contract between life sciences companies and society, there is an equally important call for the next leader of the FDA to be a person who instills trust, in addition to having the scientific knowledge to promote and protect the public’s health,” said Robert Stanislaro, a Senior Managing Director and Head of the Healthcare & Life Sciences’ Corporate Reputation offering within the
While a new concept just 18 months ago, virtual events are expected to continue to be an important engagement strategy for the industry moving forward; however, industry leaders look forward to the resumption of in-person events in 2022. According to the survey:
- Over the last 12 months, favorability of virtual healthcare conferences has increased from 53% to 69%.
- While 80% claim virtual conferences will remain a crucial part of company marketing strategies in the next year, an emphatic 85% support the return of in-person healthcare industry conferences and events in 2022.
To review the full survey report, please visit here.
About the Survey
This research was conducted online by FTI Consulting’s Americas Digital & Insights team from
555 12th Street NW
Source: FTI Consulting, Inc.